Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2017-04-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
关于公司募集资金年度存放与实际使用情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "鉴证报告" (Verification Report) regarding the annual deposit and actual use of raised funds by 葵花药业集团股份有限公司 (Kwaihua Pharmaceutical Group Co., Ltd.). It references compliance with regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the management and use of raised funds. The document includes detailed financial data on the raised funds, their usage, storage, and changes in investment projects, along with auditor verification and opinions. The presence of an auditor's verification report and detailed financial data about the use of raised funds indicates this is a standalone audit or verification report related to fundraising activities, not a full annual report or interim report. It is not a simple announcement or certification but a substantive report on the use of capital raised by the company. Therefore, the document fits best under the category of Audit Report / Information (AR). FY 2016
2017-04-27 Chinese
东海证券股份有限公司关于公司2016年度募集资金存放及使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (东海证券股份有限公司) regarding the storage and use of funds raised by 葵花药业集团股份有限公司 in 2016. It references regulatory rules related to securities issuance and listing, details the amount of funds raised, their allocation, usage, and compliance with relevant regulations. The document includes audit verification reports and bank statements, and concludes with a formal opinion on the compliance and proper use of the raised funds. This type of document is a formal audit or verification report on fundraising activities and fund usage, not a full annual report or earnings release. It is not a simple announcement or certification but a substantive audit-related report on fundraising compliance. Therefore, it fits best under the category Audit Report / Information (AR). FY 2016
2017-04-27 Chinese
东海证券股份有限公司关于公司首次公开发行股票2016年度保荐工作报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2016年度保荐工作报告" which translates to "2016 Annual Sponsorship Work Report" related to the initial public offering (IPO) of a company. It is issued by 东海证券股份有限公司 (Donghai Securities Co., Ltd.) as the sponsor for 葵花药业集团股份有限公司 (Kwaihua Pharmaceutical Group Co., Ltd.). The content includes detailed descriptions of the sponsor's work in reviewing disclosures, supervising fundraising, governance oversight, on-site inspections, and other compliance and supervisory activities during the IPO process. It is not a full annual report of the company, nor is it an earnings release or a regulatory filing. It is a specialized report related to the sponsor's duties during the IPO process, which aligns with the category of Audit Report / Information (AR) as it involves audit-related supervisory work and independent opinions on the IPO process and company disclosures. The document length is 2625 characters, which is relatively short but contains substantive content about the sponsor's work rather than just an announcement or certification. Therefore, the best fitting category is AR (Audit Report / Information). FY 2016
2017-04-27 Chinese
2017年第一季度报告正文
Interim / Quarterly Report Classification · 95% confidence The document is titled as the "2017年第一季度报告正文" which translates to "2017 First Quarter Report". It contains detailed financial data such as revenue, net profit, cash flow, asset and liability changes, shareholder information, and management's discussion of financial performance and outlook for the first quarter of 2017. The length of the document (over 14,000 characters) and the presence of substantive financial statements and analysis confirm it is a comprehensive quarterly report. This matches the definition of an Interim / Quarterly Report (IR). There is no indication that this is merely an announcement or a certification, and it is not an annual report or earnings release. Therefore, the correct classification is IR with high confidence. Q1 2017
2017-04-27 Chinese
第二届监事会第十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding various reports and proposals related to the 2016 fiscal year and the first quarter of 2017. It includes approvals of the 2016 annual report, 2017 Q1 report, financial statements, profit distribution plan, internal control reports, and other governance matters. The document is a formal meeting resolution and does not contain the full financial reports themselves but references them and states that they will be submitted to the shareholders' meeting for approval. The document length is 4117 characters, which is relatively short and consistent with a meeting resolution or announcement rather than a full report. This fits best with the category of Regulatory Filings (RNS), as it is a general regulatory announcement about supervisory board meeting resolutions and approvals, not the actual annual or quarterly reports themselves.
2017-04-27 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" (Internal Control Assurance Report) and includes detailed evaluation and explanation of the company's internal control effectiveness related to financial reporting for the year ended December 31, 2016. It is issued by an accounting firm (瑞华会计师事务所) and includes an internal control self-evaluation report by the company. The content focuses on internal control assessment, defect identification, and remediation measures, which aligns with audit-related assurance services rather than a full annual report or interim financial report. The document length is substantial (13,571 characters) and contains detailed substantive content, not merely an announcement or certification. Therefore, it fits the category of an Audit Report / Information (AR), which covers standalone audit reports and internal control evaluation reports. FY 2016
2017-04-27 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.